CCT3 promotes tumor proliferation, Sorafenib resistance, and ferroptosis sensitivity [41], while CCT6A regulates the G1‐to‐S phase transition, contributing to cell cycle dysregulation and tumor progression [46]. This evidence concerns the gene CCT6A and neoplasm.